CV Sciences 3Q 2026: Revenue $3.03M, EPS ($0.00) — 10-Q Summary
CV Sciences reported 3Q 2026 revenue of $3.03M, down 7% YoY, with net loss narrowing to $93K. Sales volume and prices declined due to state regulations and higher discounts, but gross margin improved to 50%. New products contributed 48.4% of revenue. A legal settlement gain of $500K also impacted results.
How this was made

The 30-second read
Why it matters
The earnings release provides the first public numbers for the quarter, offering fresh data for traders.
Market read
Micro‑cap earnings with limited market impact; primarily relevant to niche investors.
What to watch
Potential upside from new product launches accounting for 48% of revenue.
Background
CV Sciences filed its Q3 2026 10‑Q, reporting modest revenue decline and loss improvement.
Ticker impact
Q3 2026 10-Q shows revenue down 7% YoY to $3.03M and net loss narrowing, with a $500K legal settlement gain.
likely modest pressure as investors price in lower revenue and modest loss narrowing.
Micro‑cap earnings with small absolute numbers; market reaction typically muted.
Market effects
Limited impact on the broader hemp‑derived products sector.
Minimal effect on U.S. markets given the company's small size.
Negligible.
Counterpoint
If the settlement gain signals resolution of legal risk, the stock could rebound despite revenue decline.
Key entities
- companyCV Sciences, Inc.
Micro‑cap hemp‑derived product manufacturer.


